Company: TYRA
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0000950170-25-046124
Chunk: 13

Company: Tyra Biosciences, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 13
---
-house and we retain full development and commercialization rights for our pipeline. We intend to maximize the value of our pipeline by retaining development and commercialization rights to our product candidates, indications and geographies that we believe we can ultimately commercialize successfully on our own if they are approved. We will seek to collaborate on product candidates or indications that we believe have promising utility in disease areas or patient populations that are better served by the resources or specific expertise of larger biopharmaceutical companies.  

Our SNÅP Platform

Our proprietary SNÅP platform enables rapid and precise drug design through iterative molecular SNÅPshots that help us design and predict which product candidates will demonstrate the highest potency, selectivity and tolerability in the clinic. Through this approach, we have developed next-generation precision small molecule candidates with novel structures designed to inhibit the target while avoiding off-target toxicities and resistance mutations.  

Our SNÅP platform is driven by our ability to generate iterative data rapidly and concurrently from the following three key pillars. 

1.Protein crystallography. We have developed proprietary protein crystallography techniques that enable us to determine the co-crystal structures of newly synthesized compounds in target proteins in as little as three days. This enables weekly generation of detailed structural insights on the precise interactions and conformational changes that occur when our potential product candidates bind to a particular target, creating opportunities to further refine the structural design. 

2.Cell-based assays. We assess inhibitor potency directly in in vitro target-specific anti-proliferation assays, in addition to enzymatic assays, to enable us to simultaneously understand target potency and cell penetration as well as target-specific cell killing. Our process allows us to generate data on newly synthesized compounds in as little as two days. 

3.In vivo models. Our direct structural insights and in vitro datasets are complemented by in vivo pharmacologic data generated through in-house animal models that provide us with bioavailability, PK data and anti-tumor activity in as little as five days. 

Together, these three pillars of our platform provide a molecular SNÅPshot for our compound candidates. At this time, we are able to generate a molecular SNÅPshot for a compound candidate within one week. We believe that a sharp focus on efficiently generating these three key empirical datasets for compound candidates enables us to 

5

balance speed with the robust identification of pivotal insights to rapidly and precisely iterate the design of our novel molecular structures. 

Overcoming First Generation FGFR Inhibitor Liabilities

We have initially